Investigational drug · Phase 3
SYS6043
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
7
Any phase or sponsor naming "SYS6043"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6043", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Advanced/Metastatic Solid Tumors
- HCC - Hepatocellular Carcinoma
- Platinum-resistant Ovarian Cancer
- Platinum-resistant Primary Peritoneal Cancer
- Platinum-resistant Fallopian Tube Cancer
Approved drugs for the same conditions: Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6043" as an intervention, largest first.
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07415863 · 820 participants (planned) · Start Dec 30, 2024 · Primary completion Dec 30, 2027
Drug: SYS6043 · For: Advanced/Metastatic Solid Tumors
Sites: Beijing, China
- A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast CancerPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07879911 · 550 participants (planned) · Start Nov 30, 2026 · Primary completion Nov 30, 2028
Drug: Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043; Investigator's Choice of Chemotherapy (paclitaxel,nab paclitaxel,capecitabine,eribulin,carboplatin) · For: Triple Negative Breast Cancer
- A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube CancersPivotal-lookingRecruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07708753 · 460 participants (planned) · Start Jul 15, 2026 · Primary completion Oct 1, 2029
Drug: SYS6043; Liposomal doxorubicin, paclitaxel, or topotecan · For: Platinum-resistant Ovarian Cancer; Platinum-resistant Primary Peritoneal Cancer; Platinum-resistant Fallopian Tube Cancer
Sites: Beijing, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07241936 · 444 participants (planned) · Start Nov 13, 2025 · Primary completion Oct 30, 2027
Drug: sirolimus (albumin-bound); DP303c and 3 more · For: Advanced Solid Tumors
Sites: Shanghai, China
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07833735 · 400 participants (planned) · Start Oct 15, 2026 · Primary completion Oct 15, 2028
Drug: SYS6043; bevacizumab and 1 more · For: Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.Industry
NCT07424547 · 386 participants (planned) · Start Mar 3, 2026 · Primary completion Dec 2029
Drug: SYS6043 · For: Cancer; Solid Tumor Cancer; Advanced Metastatic Cancer and 4 more
Sites: Plantation, Florida; Austin, Texas; San Antonio, Texas · 5 sites in all
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07761286 · 288 participants (planned) · Start Sep 30, 2026 · Primary completion Sep 30, 2029
Drug: SYS6090 Injection + Bevacizumab Injection; SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection and 1 more · For: HCC - Hepatocellular Carcinoma
Sites: Harbin, China
Newest research
PubMed records naming it or its code names, newest first.
- "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers.
· Cancer Discov 2026
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.